What is depression ?

There are several categories of mood disorders (unipolar, bipolar, seasonal depression…) that are characterized by the appearance and recurrence of Major Depressive Episodes” (MDE).

A major depressive episode is not a reactionary sadness or a state of malaise, but is characterized by the presence of five of nine symptoms (sad mood, anhedonia, weight loss or gain, sleep disorders, feelings of guilt, etc.) persisting for at least two weeks, and by a change in the patient’s daily life compared to his or her previous situation.

None of these symptoms can be explained by grief or attributable to the direct physiological effects of a drug or other medical condition. The symptoms are accompanied by suffering felt by the subject or by those around him/her, and by an alteration in social and professional functioning.

The diagnosis of a major depressive episode is clinical and therefore subjective, insofar as there is currently no known biological test to confirm it. Diagnostic tools (standard questionnaires) have been developed to try to reduce this subjectivity in the field of research.

The etiology of these disorders is poorly understood, although the interaction of several biological factors (including genetic predisposition) and environmental factors (stress, emotional deprivation, abuse, etc.) is suspected.


According to the World Health Organization :

          ✔  The prevalence of depression is 5-10% of the population,

          ✔  8-20% of the population will experience it in their lifetime,

          ✔  There is no ethnic or racial influence on the prevalence of depression

          ✔  15% to 20% of patients with mood disorders attempt suicide

          ✔  Up to 50% of chronic sick leave is due to depression and anxiety

          ✔ depression is the world’s leading cause of disability

The different treatments for depression

The primary treatments for major depressive episodes are antidepressant drugs and psychotherapy.

  • Antidepressant

The treatment of depression is primarily based on medication. There are several types of antidepressants with different mechanisms of action, which offers doctors several therapeutic possibilities (monotherapies, dual therapies, etc.). At least three weeks of treatment are necessary before a thymic improvement appears.

Drug treatments are effective in 60% to 70% of cases1. In the other cases, the term “drug resistance” is used.

  • Psychotherapy

The psychotherapies used are of several types (psychodynamic therapies, cognitive and behavioural therapies, etc.) and vary greatly in duration (from several weeks to several years). They are effective after several weeks and require the active participation of the patient, which sometimes makes them unsuitable for the acute phases of the depressive episode, particularly in the case of melancholic states.

They are mainly used in the long term, generally as a complement to other treatments, and to prevent recurrence.

  • Electroconvulsive therapy

Electroconvulsive therapy (ECT) (formerly seismotherapy) involves inducing an epileptic seizure by delivering a weak and very brief electric current through electrodes applied to the skull. It is performed under general anaesthesia. It is more effective than antidepressants and is also faster. It is used to treat the most severe depression, drug-resistant depression, or when other treatments are contraindicated.

[More information…]

Transcranial Magnetic Stimulation

Numerous studies and meta-analyses have demonstrated the effectiveness of Transcranial Magnetic Stimulation (TMS) in the treatment of depression10-18. As a result, TMS is now the subject of numerous recommendations:

rTMS is covered by the healthcare systems of several industrialized countries (Germany, Netherlands, United States, Canada, Australia, New Zealand, Israel, etc.).

  • How does a Transcranial Magnetic Stimulation (TMS) treatment work?


Treatment of depression with Transcranial Magnetic Stimulation (TMS) generally consists of daily sessions of about 20 minutes repeated over a period of 3 to 6 weeks. As TMS is minimally invasive, these sessions are often carried out on an outpatient basis. These repeated stimulations will lead to the modulation of the neuronal activity of a brain network involved in mood regulation.

The brain area stimulated in the first instance, belonging to a region of the brain called the dorsolateral prefrontal cortex (or DPLFC), is located at the junction of Brodman’s areas 9 and 46. The Syneika One neuronavigator precisely defines this target according to the patient’s brain anatomy, and guides the manipulator to accurately position the TMS coil.

This target will be stimulated at “high frequency” (usually 10 Hz) in case of stimulation on the left hemisphere, or at “low frequency” (1Hz) in case of stimulation on the right hemisphere.

The optimisation of the expected therapeutic effect of rTMS requires rigorous control, over the course of the sessions, of the procedure for locating the stimulation probe in relation to the target cortical area3.

This control is carried out by the Syneika One neuronavigator.

  • Effectiveness of Transcranial Magnetic Stimulation TMS


The expected result at the end of the first weeks of stimulation is a positive response for one patient out of two (50% reduction in score on a Hamilton scale) and remission for 20% of patients (HDRS<8)4, 19.

If symptoms do not improve sufficiently, the doctor may first suggest moving on to the target in the opposite hemisphere5, 6, 19. Other cortical targets could also be used, such as the dorsomedial prefrontal cortex7 or the orbitofrontal cortex8.

  • What are the side effects of Transcranial Magnetic Stimulation ?


The most common side effects of TMS in the treatment of depression are headaches or discomfort at the stimulation site, experienced by a third of patients, especially during the first sessions. These side effects generally disappear spontaneously after the session.

Discover the health care institutions practicing TMS, and equipped by Syneika in France :

  • 1 Fagiolini A, Kupfer DJ. Is treatment-resistant depression a unique subtype of depression? Biol Psychiatry. 2003 Apr 15;53(8):640-8. doi:10.1016/s0006-3223(02)01670-0. PMID: 12706950
  • 2 Lefaucheur JP, Aleman A, Baeken C, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018). Clin Neurophysiol. 2020;131(2):474-528, doi:10.1016/j.clinph.2019.11.002
  • 3 Bulteau S. Guirette C, Vanelle JM, Sauvaget A. Utilisation de la TMS dans le traitement des troubles de l’humeur. Dans : Poulet E, Bubrovsky M, Bulteau S, Haesebaert F, directeurs.  Stimulation Magnétique Transcranienne répétée: Applications en psychiatrie. Presse Universitaire François Rabelais ; 2019. P.130.
  • 4 Blumberger DM, Vila-Rodriguez F, Thorpe KE, et al: Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet 2018; 391:1683–1692. doi:10.1016/S0140-6736(18)30295-2
  • 5 Fitzgerald PB, McQueen S, Herring S, et al. A study of the effectiveness of high-frequency left prefrontal cortex transcranial magnetic stimulation in major depression in patients who have not responded to right-sided stimulation. Psychiatry Res. 2009;169(1):12-15. doi:10.1016/j.psychres.2008.06.017
  • 6 Fitzgerald PB, Hoy KE, Elliot D, McQueen S, Wambeek LE, Daskalakis ZJ. Exploring alternative rTMS strategies in non-responders to standard high frequency left-sided treatment: A switching study. J Affect Disord. 2018;232:79-82. doi:10.1016/j.jad.2018.02.016
  • 7 Bakker N, Shahab S, Giacobbe P, et al. rTMS of the dorsomedial prefrontal cortex for major depression: safety, tolerability, effectiveness, and outcome predictors for 10 Hz versus intermittent theta-burst stimulation. Brain Stimul. 2015;8(2):208-215. doi:10.1016/j.brs.2014.11.002
  • 8 Feffer K, Fettes P, Giacobbe P, Daskalakis ZJ, Blumberger DM, Downar J. 1Hz rTMS of the right orbitofrontal cortex for major depression: Safety, tolerability and clinical outcomes. Eur Neuropsychopharmacol. 2018;28(1):109-117. doi:10.1016/j.euroneuro.2017.11.011
  • 9 Loo CK, McFarquhar TF, Mitchell PB. A review of the safety of repetitive transcranial magnetic stimulation as a clinical treatment for depression. Int J Neuropsychopharmacol. 2008 Feb;11(1):131-47. doi:10.1017/S1461145707007717. Epub 2007 Sep 20. PMID: 17880752.
  • 10 Kedzior KK, Azorina V, Reitz SK. More female patients and fewer stimuli per session are associated with the short-term antidepressant properties of repetitive transcranial magnetic stimulation (rTMS): a meta-analysis of 54 sham-controlled studies published between 1997-2013Neuropsychiatr Dis Treat. 2014;10:727-756. Published 2014 May 7. doi:10.2147/NDT.S58405
  • 11 Berlim MT, van den Eynde F, Tovar-Perdomo S, et al. Response, remission and drop-out rates following high- frequency repetitive transcranial magnetic stimulation (rTMS) for treating major depression: a systematic review and meta- analysis of randomized, double-blind and sham-controlled trials. Psychol Med. 2014;44:225-239. https://doi.org/10.1017/s0033291713000512
  • 12 Hovington CL, McGirr A, Lepage M, Berlim MT. Repetitive transcranial magnetic stimulation (rTMS) for treating major depression and schizophrenia: a systematic review of recent meta-analyses. Ann Med. 2013 Jun;45(4):308-21. doi: 10.3109/07853890.2013.783993. Epub 2013 May 20.
  • 13 Leggett LE, Soril LJ, Coward S, Lorenzetti DL, MacKean G, Clement FM. Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression in Adult and Youth Populations: A Systematic Literature Review and Meta-Analysis. Prim Care Companion CNS Disord. 2015 Nov 5;17(6):10.4088/PCC.15r01807. doi: 10.4088/PCC.15r01807.
  • 14 Gaynes BN, Lloyd SW, Lux L, Gartlehner G, Hansen RA, Brode S, Jonas DE, Swinson Evans T, Viswanathan M, Lohr KN. Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis. J Clin Psychiatry. 2014 May;75(5):477-89; quiz 489. doi: 10.4088/JCP.13r08815.
  • 15 Brunoni AR, Chaimani A, Moffa AH, Razza LB, Gattaz WF, Daskalakis ZJ, Carvalho AF. Repetitive Transcranial Magnetic Stimulation for the Acute Treatment of Major Depressive Episodes: A Systematic Review With Network Meta-analysis. JAMA Psychiatry. 2017 Feb 1;74(2):143-152. doi: 10.1001/jamapsychiatry.2016.3644. Erratum in: JAMA Psychiatry. 2017 Apr 1;74(4):424.
  • 16 Hyde J, Carr H, Kelley N, Seneviratne R, Reed C, Parlatini V, Garner M, Solmi M, Rosson S, Cortese S, Brandt V. Efficacy of neurostimulation across mental disorders: systematic review and meta-analysis of 208 randomized controlled trials. Mol Psychiatry. 2022 Jun;27(6):2709-2719. doi: 10.1038/s41380-022-01524-8. Epub 2022 Apr 1.
  • 17 O'Reardon JP, Solvason HB, Janicak PG, Sampson S, Isenberg KE, Nahas Z, McDonald WM, Avery D, Fitzgerald PB, Loo C, Demitrack MA, George MS, Sackeim HA. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry. 2007 Dec 1;62(11):1208-16. doi: 10.1016/j.biopsych.2007.01.018. Epub 2007 Jun 14.
  • 18 George MS, Lisanby SH, Avery D, McDonald WM, Durkalski V, Pavlicova M, Anderson B, Nahas Z, Bulow P, Zarkowski P, Holtzheimer PE 3rd, Schwartz T, Sackeim HA. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry. 2010 May;67(5):507-16. doi: 10.1001/archgenpsychiatry.2010.46.
  • 19 Milev RV, Giacobbe P, Kennedy SH, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 4. Neurostimulation Treatments. The Canadian Journal of Psychiatry. 2016;61(9):561-575. doi:10.1177/0706743716660033